Comparison of Treatment Guidelines for Ulcerative Colitis: Role of Biologics.
10.4166/kjg.2018.71.4.192
- Author:
Jung Ho BAE
1
;
Dong Hoon YANG
Author Information
1. Department of Internal Medicine, Healthcare System Gangnam Center, Seoul National University Hospital, Seoul, Korea.
- Publication Type:Brief Communication
- Keywords:
Ulcerative colitis;
Tumor necrosis factor-alpha;
Biological products
- MeSH:
Antibodies;
Biological Factors;
Biological Products*;
Colitis;
Colitis, Ulcerative*;
Colon;
Diarrhea;
Inflammation;
Necrosis;
Quality of Life;
Tumor Necrosis Factor-alpha;
Ulcer*
- From:The Korean Journal of Gastroenterology
2018;71(4):192-195
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Ulcerative colitis (UC) is a chronic inflammatory condition of the colon, characterized by diffuse mucosal inflammation with bloody diarrhea. The therapeutic goals in UC have evolved from symptomatic relief to deep remission, including sustained steroid-free clinical remission, mucosal healing, and ideally histologic remission. The management of UC has significantly been improved by advance of biologic agents including anti-tumor necrosis factor alpha (TNF-α) antibodies. Anti-TNF-α agent have progressively been introduced earlier in treatment algorithms for UC in order to minimize steroid exposure and dependence and to maximize disease control and quality of life. We reviewed the therapeutic recommendations of biologic agents for UC in the Korean and European Crohn's and Colitis Organization guidelines.
